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Statement of Translational Relevance
Venous thromboembolism (VTE) is a frequent complication and leading cause of death in patients with cancer. Prophylactic anticoagulation (PA) has been shown to reduce the risk of cancer-associated VTE by half, but comes at the cost of an increased risk of bleeding. Biomarkers hold great promise to identify cancer patients with the highest VTE risk and net clinical benefit of PA, while sparing low-VTE-risk cancer patients from PAassociated bleeding complications. In this study, we report the identification of a novel biomarker for cancer-associated VTE, soluble Vascular Endothelial Growth Factor-A (sVEGF). We observed a significant association between elevated sVEGF and an excessively increased risk of VTE during a 2-year prospective follow-up of 804 cancer patients.
This prognostic relationship was independent of major other prognostic factors for VTE, such as tumor type and stage. We propose sVEGF as a candidate biomarker for the personalization of VTE prophylaxis in patients with malignant diseases.
Introduction
Venous thromboembolism (VTE) is a frequent complication and leading cause of death in cancer patients.(1) Several individual risk factors related to patient-, tumor-and treatment characteristics determine the substantially increased overall risk of VTE in the cancer population.(2) While primary thromboprophylaxis conceptually appears as a meaningful strategy to reduce the burden of cancer-associated VTE, its implementation is hampered by the great variation of VTE risk between patients. (3) In this respect, recent progress has been made via the development of risk-scoring models that facilitate the identification of patients at a high risk of VTE. (4, 5) Importantly, it has been demonstrated that the addition of selected biomarkers to pre-existing risk-scoring models can increase the prognostic performance of these models. (6) Further improvement of such scores by the identification of new prognostic biomarkers for VTE is believed to facilitate targeting thromboprophylaxis to the patients with the greatest net clinical benefit while sparing low risk patients from potential bleeding complications. (7) Vascular endothelial growth factor A (VEGF) is a key regulator and stimulating agent of angiogenesis, (8) which promotes the formation of highly thrombogenic and leaky tumor vessels that are necessary for maintaining oxygen and energy supply at the site of the tumor lesion.(9) VEGF further induces the expression of tissue factor (TF), the main initiator of the coagulation cascade in vivo, on endothelial cells.(10) TF activity has been shown to be increased more than 100-fold after the exposition to VEGF and tumor necrosis factor alpha (TNF-α).(11) Elevated levels of VEGF are present in the bloodstream of patients with highly prothrombotic malignancies, such as ovarian and renal carcinomas, (12) and have been reported to be associated with primary resistance to chemotherapy and increased mortality. (13) (14) (15) 
Methods

Study population and Design
In this study, we analyzed 804 patients from the Vienna Cancer and Thrombosis Study (CATS), an ongoing cohort study to investigate prognostic factors and biomarkers for VTE in cancer patients. The 804 patients in this analysis were enrolled between October 2003 and March 2008. The exact inclusion and exclusion criteria of CATS were described extensively in previous reports. (18, 19) Briefly, patients 18 years or older with newly-diagnosed malignancy or disease progression after complete or partial remission were recruited after written informed consent and followed-up for 2 years until the occurrence of VTE, death, or censoring alive. The following tumor sites were included: blood (myeloma and lymphoma), brain, breast, bronchus, colorectal, kidney, pancreas, prostate, and "selected others" (mainly sarcomas and gynaecologic tumors)). Exclusion criteria were clinically overt infection, thromboembolic events (both arterial and venous) within the last 3 months, and continuous anticoagulation. Patients that underwent surgery or radiotherapy within the past 2 weeks before recruitment, and/or chemotherapy within the past 3 months were ineligible. At baseline, study patients underwent a detailed interview and chart review to ascertain clinicopathological variables, and venous blood samples were taken for storage in our biobank. The study protocol was approved by the local institutional review board before any patient-related activities took place (EC number: 126/2003, ethik-kom@meduniwien.ac.at).
Outcome Measures
The primary endpoint of this study was symptomatic non-fatal and fatal VTE. Diagnosis of VTE had to be confirmed by objective methods (duplex ultrasound or venography for deep vein thrombosis (DVT), ventilation/perfusion scan or computed tomography (CT) of the chest for non-fatal pulmonary embolism (PE), and autopsy records for fatal PE). VTE events were independently adjudicated by an external committee consisting of experts in diagnostic radiology and vascular medicine. No routine screening for VTE was performed. Incidentally discovered VTE (e.g. PE on restaging CT scans) was counted as an event given the independent adjudication committee deemed the VTE event to be of clinical significance.
Secondary endpoint was death-from-any-cause.
Laboratory analysis
Baseline venous blood samples were obtained by atraumatic antecubital venipuncture for laboratory analysis. Biomarker measurements (sVEGF and others) were performed in plateletpoor citrated plasma, which was obtained by drawing baseline blood into citrate vacuum tubes (Vacuette; Greiner-Bio-One, Kremsmuenster, Austria; 9 parts blood and 1 part sodium citrate (concentration: 0.129 mmol/L)) and centrifuged at 3000g for 10 minutes to obtain plateletpoor plasma. Plasma aliquotes were stored at −80°C until testing was performed in series.
sVEGF was measured by a multiplex immunoassay (xMAP technology from Luminex (Riverside, CA, USA; sVEGF detection limit=0.5pg/mL)). Specific anti-VEGF antibodies as well as recombinant growth factors were obtained from R&D Systems (Minneapolis, MN, USA). The biomarkers D-Dimer, soluble P-Selectin (sP-Selectin), peak of thrombin generation, prothrombin fragment 1.2, and coagulation factor VIII activity (FVIII) were measured as described in previous reports. (18) (19) (20) (21) (22) 
Statistical Analysis
All statistical analyses were performed using Stata (Windows version 13, Stata Corp., Houston, TX) and R (Version 3.1.1., The R core development team, Vienna, Austria).
Continuous variables were summarized with medians (25 th -75 th percentile), whereas categorical data were described by absolute frequencies and percentages. The correlation To study the association between VEGF and the rate of VTE, we performed a cause-specific analysis of VTE hazards using log-rank tests and Cox regression. (24) In contrast, the association between VEGF and the absolute risk of VTE was studied with a subdistribution approach using Gray's test (R library cmprsk) and Table 1) . The majority of patients suffered from newly-diagnosed malignancy (n=596, 74.1%), and had no clinical evidence for metastatic disease (n=467, 58.1%).
Five-hundred-forty-nine (68.3%) out of 804 patients had sVEGF levels above the detection limit of 0.5pg/mL ( Table 2) . A group of patients with elevated baseline sVEGF (n=197) was defined by dichotomizing sVEGF into a binary variable at the 75 th percentile of its distribution (Q3, cut-off: 17.65pg/mL; >Q3 defines the "elevated sVEGF" group). On average, patients with elevated sVEGF had higher platelet counts, lower haemoglobin, as well as higher levels of D-Dimer and peak thrombin generation ( 
sVEGF and the risk of VTE
In the overall study population, the cumulative incidence of VTE at 6, 12, and 24 months of follow-up was 5.0%, 6.2%, and 6.9%, respectively. Patients with elevated sVEGF (i.e. >Q3)
had a higher rate of VTE than patients with sVEGF≤Q3 (log-rank test p=0.02). The cumulative 6-, 12-, and 24-month incidences of VTE (95%CI) were 8.6% (5.2-13.1), 10.2% (6.4-14.9) and 10.2% (6.4-14.9) in the VEGF>Q3 group, and 3.8% (2.5-5.6), 5.0% (3.5-7.0) and 5.9% (4.2-7.9) in the sVEGF≤Q3 group, respectively (Gray's test p=0.03, Figure 1 ).
In univariable competing risk regression, a 10 pg/ml increase in sVEGF was associated with a 4% increase in the risk of VTE (subhazard ratio (SHR)=1.04, 95%CI: 1.00-1.09, p=0.04, Table 3 ). In univariable cause-specific hazard analysis, a 10 pg/ml increase in sVEGF was associated with a 5% increase in the rate of VTE (hazard ratio (HR)=1.05, 95%CI: 1.00-1.09, p=0.03). After multivariable adjustment for selected clinical and laboratory parameters ("multivariable model"), the associations between VEGF and the risk and rate of VTE prevailed (Table 3 ). In the analysis of potential interactions between sVEGF and selected covariates (tumor type, D-Dimer, and CRP), the association between sVEGF and VTE appeared to be modified by D-Dimer, and vice versa (SHR for interaction term=1.01, 95% CI:
1.00-1.01, p<0.001).
Comparing the increase in VTE risk for 1 standard deviation increase in sVEGF with the already-established VTE biomarkers D-Dimer, sP-Selectin, peak of thrombin generation, 
sVEGF and the risk of Death
In the overall study population, the cumulative probability of death at 6, 12, and 24 months of 
Discussion
In this prospective cohort study, we have provided evidence for an association between elevated levels of sVEGF and a higher risk of VTE in patients with cancer. Furthermore, we could confirm the association of elevated sVEGF and poor overall survival.
sVEGF and the pathogenesis of VTE in cancer
Using a sVEGF multiplex immunoassay we found that sVEGF was present in the bloodstream of approximately 70% of the investigated patients. Interestingly, the other 30% of patients with undetectable sVEGF experienced only half the risk of developing VTE. It was well established in experimental studies that endothelial cells and several subsets of leukocytes can express sVEGF on their surface, (10, 16) and that activated platelets release VEGF from their alpha-granules.(17) Surprisingly, we found that leukocyte and platelet count explained less than 3% of the variation in sVEGF, which increased to 7% when we considered vWF and LDH -among others -as independent variables. Given that vWF and sP-Selectin are contained in alpha-granules, (25) Importantly, our analysis of cause-specific VTE hazards identified a temporal relationship between increased sVEGF at baseline and an increased rate of VTE during a follow-up period of two years. This association was independent of other known risk factors for VTE, such as high-risk tumor types, as well as a panel of biomarkers indicative of in vivo hypercoagulability. This supports the concept of a pathogenetic connection between sVEGF and cancer-associated VTE.
We further observed an association between increased sVEGF and death that was robust to the multivariable correction for other prognostic variables, such as high-risk tumor sites, metastatic disease, and D-Dimer. The connection between sVEGF and mortality in cancer has already been described in previous studies, and we can re-confirm these results. (13, 14) sVEGF and its potential utility as a biomarker for VTE prediction in cancer patients We investigated the relationship between sVEGF and the absolute risk of VTE using competing risk analysis. In univariable analysis, we found an association between increased sVEGF and a higher risk of VTE. The prognostic relationship between sVEGF and VTE risk prevailed after multivariable adjustment for established VTE risk factors and candidate biomarkers for cancer-associated VTE, such as high-risk tumor types and sP-Selectin. To compare the "effect sizes" on VTE between sVEGF and other biomarkers, we brought all markers on a common scale (i.e. Z-standardization). This allowed us to appreciate how much the risk of VTE changes for 1 unit (i.e. 1 SD) increase in the biomarkers. Here, the risk ratios of sVEGF and D-Dimer were very similar, and higher for peak of thrombin generation, prothrombin fragment 1.2, and sP-Selectin. Based on these standardized comparisons we cannot conclusively answer the question whether e.g. sP-Selectin is a better VTE biomarker than sVEGF or D-Dimer, as this would necessitate further elaborate analyses that are beyond the scope of this manuscript. Interestingly, we observed a positive interaction between sVEGF and D-Dimer. This could indicate that that the predictive potential of sVEGF for VTE could be greater in patients with elevated D-Dimer, and vice versa.
Limitations of the study
Previous reports in cancer patients have described a relationship between increased sVEGF and disease progression. (12, 29) Besides its adverse impact on survival, disease progression is also a strong risk factor for VTE.(1) Unfortunately, no data are available on disease progression in our study. Further, due to the relatively low VTE event rate (n=55 VTE events), we had to refrain from extensive multivariable selection and model building. Finally, the cut-off for elevated sVEGF at the 75 th percentile was chosen arbitrarily. However, as no data are currently available on plasma sVEGF reference ranges or clinically validated cut-offs in the cancer population, we pragmatically pre-specified this cut-off at the 75 th percentile, which is frequently used in studies where validated cut-offs are unavailable, and did not investigate any other cut-offs in order to preserve the type I error rate.
Research. 
Conclusion
We demonstrated a prospective association between elevated plasma sVEGF and an increased risk of VTE in patients with cancer. This association was independent of major known prognostic factors, such as tumor type and biomarkers indicative of a prothrombotic state.
Further, we confirmed the role of increased sVEGF as an adverse prognostic factor for mortality. In conclusion, we propose sVEGF as a novel biomarker for cancer-associated VTE.
